Isosorbide Mononitrate vs. Isosorbide Dinitrate: Key Differences
Isosorbide mononitrate (ISMN) is the active metabolite of isosorbide dinitrate (ISDN) and offers superior pharmacokinetic properties with 100% bioavailability, no first-pass metabolism, and more predictable dosing compared to ISDN, which undergoes extensive hepatic first-pass metabolism. 1
Pharmacokinetic Differences
Bioavailability and Metabolism
- ISMN: Nearly 100% bioavailable after oral administration with ideal, dose-linear kinetics. It is NOT subject to first-pass hepatic metabolism 1
- ISDN: Undergoes extensive first-pass metabolism in the liver, converting to both 2-mononitrate and 5-mononitrate (the active metabolites), which complicates its pharmacokinetics 2
Plasma Concentrations and Predictability
- ISMN: Achieves maximum plasma concentrations in 30-60 minutes with predictable, linear pharmacokinetics. The elimination half-life is approximately 5 hours 1
- ISDN: Has complex kinetics due to metabolism into active mononitrates that accumulate more than the parent drug during long-term treatment, making concentration-response relationships difficult to establish 2
Clinical Dosing Implications
Dosing Frequency
According to guidelines 3:
- ISMN: Can be dosed once or twice daily (20 mg twice daily for immediate-release; 60-240 mg once daily for extended-release)
- ISDN: Requires 2-3 times daily dosing (5-80 mg, 2-3 times daily for immediate-release; 40 mg 1-2 times daily for slow-release)
Dose Efficiency
Research demonstrates that ISMN requires 1.5-2 times lower doses than ISDN to achieve equivalent antianginal effects, making it more cost-effective 4. Both drugs show comparable efficacy in reducing anginal attacks and improving exercise tolerance 4, 5.
Tolerance Development
A critical caveat: Both drugs develop tolerance with continuous administration, though the pattern differs:
- ISDN: Shows complete loss of effect during sustained four-times-daily therapy, with no significant improvement over placebo after 7 days of continuous use 6
- ISMN: Demonstrates less tolerance development, particularly with once-daily dosing that allows a nitrate-free interval. Extended-release ISMN maintains efficacy at 4 and 12 hours after dosing even during sustained therapy 6
The key to avoiding tolerance is ensuring a nitrate-free interval of several hours daily - this is more easily achieved with once-daily ISMN dosing 3.
Practical Clinical Advantages of ISMN
- Simpler dosing: Once-daily administration improves compliance 5
- Fewer side effects: Lower incidence of headache compared to ISDN (significantly fewer withdrawals due to headache) 5
- Predictable pharmacokinetics: No complex metabolite accumulation 1
- No first-pass effect: More reliable drug delivery 1
Important Safety Considerations
Both nitrates share the same contraindications 3:
- Absolute contraindication: Use within 24 hours of sildenafil, 48 hours of tadalafil (timing for vardenafil not established but generally 24 hours)
- Avoid with systolic BP <90 mmHg or >30 mmHg below baseline
- Avoid with marked bradycardia or tachycardia
The combination of phosphodiesterase inhibitors and nitrates can cause profound hypotension, MI, and death 3.
Bottom Line for Clinical Practice
Choose ISMN over ISDN for chronic angina management due to superior bioavailability, simpler once-daily dosing, better tolerance profile, and lower effective doses. Use extended-release formulations dosed once daily in the morning to maintain a nitrate-free interval overnight, minimizing tolerance development while maximizing patient compliance 1, 5, 6.